Viventia Biotech has announced that the FDA has designated the companys lead drug, Proxinium (formerly known as VB4-845), as a fast-track product for the treatment of patients with recurrent squamous cell carcinoma of the head and neck.
In The Pipeline
- Viventia Biotech has announced that the FDA has designated the company’s lead drug, Proxinium (formerly known as VB4-845), as a fast-track product for the treatment of patients with recurrent squamous cell carcinoma of the head and neck.
- Dendreon Corp. has announced that the FDA has granted fast track review status to sipuleucel-T (Provenge) for its proposed use in the treatment of asymptomatic men with metastatic, androgen-independent prostate cancer.
- NeoRx Corp. has received orphan drug designation from the FDA for the company’s investigational product picoplatin, a next-generation platinum therapy, for the treatment of small cell lung cancer.
- Myogen has achieved target enrollment of 186 patients in ARIES-1, one of the company’s two pivotal Phase III trials of ambrisentan in patients with pulmonary arterial hypertension.
- Migenix has initiated enrollment in a Phase IIb combination therapy clinical trial of celgosivir (MX-3253), supported in part through an agreement with Schering-Plough. Celgosivir is an orally administered, first-in-class alpha glucosidase 1 inhibitor, in development for the treatment of chronic hepatitis C virus infections.
- Vertex Pharmaceuticals has announced that the FDA has granted fast-track designation to VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor for the treatment of HCV infection.
- Spectrum Pharmaceuticals has announced the opening of accrual of a Phase II study evaluating the company’s lead drug candidate, satraplatin, in combination with paclitaxel (Taxol) as a first-line therapy in patients with unresectable advanced non-small cell lung cancer.
- Kosan Biosciences has initiated a Phase II clinical trial in patients with HER2-positive metastatic breast cancer, administering KOS-953 in combination with trastuzumab (Herceptin).
- Exelixis has initiated a multitrial Phase II clinical development program for XL999. The Phase II program is composed of six trials that will evaluate XL999 in a variety of cancer indications.
- Penwest Pharmaceuticals Co. has completed patient enrollment for its Phase IIa trial of PW4142, an extended-release tablet that the company is developing for the treatment of pain. PW4142 is an oral formulation of a compound that currently is available only as an injection.
- BioCryst Pharmaceuticals has initiated a Phase I/II clinical trial of Fodosine(TM) (forodesine hydrochloride), the company’s lead anticancer compound, to determine the safety of repeat doses of an intravenous (IV) formulation of the drug in patients with B-cell acute lymphoblastic leukemia.
- Keryx Biopharmaceuticals announced today the initiation of a corporate-sponsored clinical program to evaluate KRX-0401 (perifosine) as a treatment for multiple myeloma.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.